Highlights
- Fisher & Paykel Healthcare (ASX:FPH) scheduled its FY27 half-year results for 26 November 2026.
- August guidance projected half-year Revenue of approximately NZD 1.24 billion and net profit of NZD 280 million.
- Full-year FY27 revenue guidance was updated to NZD 2.47–2.57 billion using July exchange rates.
- Full-year net profit guidance was revised to NZD 525–565 million, including stated tariff-refund assumptions.
Fisher & Paykel Healthcare (ASX:FPH) designs respiratory care systems and sleep-apnoea products for hospital and home use worldwide. Its scheduled 26 November report covers the six months ended September 2026 and follows annual disclosures on patient consumables, Manufacturing and new products. On the ASX on 20 November 2026, the shares were priced at AUD 40.45, down 0.39% during trading.
Next Reporting Date and Clinical Product Mix
The company announced on 8 October that its half-year results for the six months to 30 September 2026 would be released on 26 November. The results were not yet available on 20 November. An August trading update gave numerical guidance for the half year, making the release a checkpoint for actual revenue, Earnings and management’s earlier assumptions.
FY26 Hospital Sales and Manufacturing
For the financial year ended March 2026, Hospital revenue reached NZD 1.51 billion, an increase of 18%. Hospital consumables sales grew 16%, according to the company’s full-year disclosure. These measures cover the completed FY26 period, not the September 2026 half year.
Full-Year Guidance Remains Conditional
The May FY27 ranges were superseded by the company’s 21 August update. At 31 July exchange rates, management guided to approximately NZD 1.24 billion of first-half revenue and NZD 280 million of first-half net profit. For the full year it now expected NZD 2.47–2.57 billion in Operating Revenue and NZD 525–565 million in net profit. Both profit outlooks incorporated NZD 23 million in US IEEPA Tariff refunds.
Currency movements matter because the group reports in New Zealand dollars while selling internationally and operating manufacturing facilities across jurisdictions. The August update anticipated improvement in gross Margin and assumed then-current tariffs and their application would continue through the financial year. Actual half-year reporting will test these assumptions.
August Trading Update and Margin Assumptions
The August announcement described Demand for recently released Hospital hardware and continued changes in clinical practice supporting consumables. Management also referred to operational efficiency work. The guidance assumed a continuation of the then-current trading environment, so it was not a statement of results achieved for September. A half-year comparison should identify any tariff refunds and currency assumptions included in the reported profit.
Risks to Consider
Clinical adoption rates, hospital treatment volumes, supply-chain reliability and medical-device regulation can affect performance. Timing of seasonal respiratory illnesses may change hospital demand. Tariffs and exchange rates introduce further cost or translation variability.
Equipment purchasing cycles differ from recurring consumables orders. Manufacturing efficiency plans must also be evaluated against actual capacity utilisation and operating expense. These factors create uncertainty without establishing that any adverse outcome has occurred.
What to Watch Next
The 26 November FY27 half-year release can disclose Hospital consumables, Homecare revenue, gross margin, currency impacts and any revision to the August guidance. Those measures will help differentiate demand trends from foreign-exchange and cost effects.
A further useful distinction is whether product development milestones have translated into commercial sales or remain in testing and rollout. Future updates can clarify progress without attributing specific earnings to products before those figures are reported.
Interpreting Half-Year Comparisons
The six months to September cover a different period from the completed year to March. As a result, a half-year margin or product-group trend should not be multiplied mechanically to predict an annual result.
Key Insights
The forthcoming half-year results are the principal near-term milestone. FY26 revenue and profit provide financial context, while Hospital and Homecare demand, manufacturing costs and updated exchange-rate assumptions are the central monitoring items.





_11_20_2026_10_15_01_176408.jpg)
Please wait processing your request...